Final Analysis From AVEO Pharmaceuticals' Phase 2 Trial Of Tivozanib In ... - TheStreet.com (press release) Print
TheStreet.com (press release)
... analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma (RCC).

...